This website uses cookies to enhance the user experience.
KL

Kjeld-Håkon Langeland Nilsen1972

Shareholdings
3
9
Norway Business roles
11

Roles

Management

NameRoleTotal operating incomeTotal equityShares
K
KHN HOLDING AS
Managing Director/CEO
-
2,009,708
100 %
directly
L
LANI REVISJON AS
Managing Director/CEO
-
533,851
100 %
indirectly
J
JANDERSEN KAPITAL AS
Managing Director/CEO
-
-29,685,244
50 %
indirectly

Boards

NameRoleTotal operating incomeTotal equityShares
K
KHN HOLDING AS
Chairman
-
2,009,708
100 %
directly
L
LANI REVISJON AS
Chairman
-
533,851
100 %
indirectly
J
JANDERSEN KAPITAL AS
Board Member
-
-29,685,244
50 %
indirectly
A
ADJUVANT PARTNERS AS
Chairman
-
183,020
25 %
indirectly
F
FINANCIAL ADJUVANT AS
Chairman
-
552,058
8.33 %
indirectly
H
HUBRO THERAPEUTICS AS
Board Member
-
36,467,975
5.01 %
indirectly
S
SAMEIET SKAKKEFOSSEN
Board Member
-
-
-
T
TORVUND REVISJON AS
Alternate Member
4,353,400
2,304,020
-
Last update: Apr 13, 2023

Shares owned by Kjeld-Håkon Langeland Nilsen

NameShare classTotal operating incomeTotal equityShare
K
KHN HOLDING AS
Ordinære aksjer
0
2,009,708
100 %
directly
L
LANI REVISJON AS
0
533,851
100 %
indirectly
J
JANDERSEN KAPITAL AS
0
-29,685,244
50 %
indirectly
A
ADJUVANT PARTNERS AS
0
183,020
25 %
indirectly
F
FINANCIAL ADJUVANT AS
0
552,058
8.33 %
indirectly
H
HUBRO THERAPEUTICS AS
0
36,467,975
5.01 %
indirectly
P
PCI BIOTECH AS
6,735,000
24,723,000
1.02 %
indirectly
N
NEXTERA AS
12,650,318
14,802,788
0.75 %
indirectly
A
ADJUTEC PHARMA AS
0
33,344,515
0.68 %
indirectly
O
ONCOINVENT ASA
5,790,000
54,931,000
0.55 %
indirectly
P
PCI BIOTECH HOLDING ASA
NO0010405640
0
43,986,000
0.08 %
directly 0.08 %
indirectly 0.94 %
Z
ZELLUNA ASA
NO0010851603
0
309,373,000
< 0.01 %
directly

Limited to direct ownership positions of 0.5% or more.

Last update: Jun 2, 2025